

halogen, cyano, $-OR_4$, $-(CH_2)_m-(C=O)NR_5R_6$, $[-(CH_2)_m-SO_2NR_4R_5,]$
 $-(CH_2)_m-NR_7(C=O)R_8$, $-(CH_2)_m-NR_7SO_2R_8$, $-(CH_2)_m-S(O)_xR_8$,
 $-(CH_2)_m-NR_7(C=O)NR_5R_6$, $-(CH_2)_m-NR_7(C=O)OR_9$, and $-CH=CH(CH_2)_yR_{10}$;
 R_3 is hydrogen, C_1 to C_6 linear or branched alkyl; R_4 is
 selected from hydrogen, C_1 to C_6 alkyl, and aryl; R_5 and R_6
 are independently selected from hydrogen, C_1 to C_6 alkyl,
 aryl, and C_1 to C_3 alkyl-aryl or R_5 and R_6 taken together to
 form a 4, 5, or 6 membered ring; R_7 and R_8 are independently
 selected from hydrogen, C_1 to C_6 alkyl, aryl, and C_1 to C_3
 alkyl-aryl; R_9 is selected from hydrogen, C_1 to C_6 alkyl,
 aryl, and C_1 to C_3 alkyl-aryl; R_{10} is selected from
 $-(C=O)NR_5R_6$ and $-SO_2NR_5R_6$, wherein R_5 and R_6 are defined as
 above, and $-NR_7(C=O)R_8$, $-NR_7SO_2R_8$, $-NR_7(C=O)NR_5R_6$, $-S(O)_xR_8$ and
 $-NR_7(C=O)OR_9$, wherein R_7 , R_8 , and R_9 are as defined above; y
 is 0, 1, or 2; x is 1 or 2; m is 0, 1, 2, or 3; and the
 above aryl groups and the aryl moieties of the above
 alkylaryl groups are independently selected from phenyl and
 substituted phenyl, wherein said substituted phenyl may be
 substituted with one to three groups selected from C_1 to C_4
 alkyl, halogen, hydroxy, cyano, carboxamido, nitro, and C_1
 to C_4 alkoxy, with the proviso that when R_2 is hydrogen or
 $-OR_4$ and R_4 is hydrogen, n is 0 or 1, ^{or} and the
 pharmaceutically acceptable salts thereof.

Claim 3, line 2, delete " $-(CH_2)_m-SO_2NHR_5$,".

4. (amended) A compound according to claim 1, said
 compound being selected from:

(R)-5-methoxy-3-(N-methylpyrrolidin-2-ylmethyl)-1H-
 indole;

(R)-5-bromo-3-(N-methylpyrrolidin-2-ylmethyl)-1H-
 indole;

(R)-5-(2-ethylsulfonyl ethyl)-3-(N-methylpyrrolidin-2-
 ylmethyl)-1H-indole;

[(R)-5-(2-methylaminosulfonyl ethyl)-3-(N-
 methylpyrrolidin-2-ylmethyl)-1H-indole;

(R)-5-(methylaminosulfonylmethyl)-3-(pyrrolidin-2-
 ylmethyl)-1H-indole;

(R)-5-(methylaminosulfonylmethyl)-3-(N-

methylpyrrolidin-2-ylmethyl)-1H-indole;]

(R)-5-carboxamido-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;

(R)-5-(2-methylsulfonyl-ethyl)-3-(N-methylpyrrolidin-2-yl-methyl)-1H-indole;

(R)-5-(2-methylsulfonamidoethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;

(R)-5-(2-aminosulphonylethenyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;

[(R)-5-(2-aminosulphonyl-ethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;

(R)-5-(2-N,N-dimethylaminosulphonyl-ethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;]

(R)-5-(2-phenylsulphonyl-ethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole hemisuccinate;

(R)-5-(2-ethylsulphonyl-ethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole hemisuccinate;

(R)-5-(2-phenylsulphonyl-ethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;

(R)-5-(3-benzenecarbonylamino-prop-1-enyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;

(R)-5-(2-(4-methylphenylsulphonyl)-ethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;

(R)-5-(3-methylsulphonylamino-prop-1-enyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;

(R)-5-(2-ethylsulphonyl-ethyl)-3-(N-2-propylpyrrolidin-2-ylmethyl)-1H-indole; and

(R)-5-(2-ethylsulphonyl-ethyl)-3-(pyrrolidin-2-ylmethyl)-1H-indole[; and

(R)-7-Bromo-5-(methylaminosulfonylmethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole].

11 13. (amended) A pharmaceutical composition for treating a condition selected from hypertension, depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain, and chronic paroxysmal hemicrania and headache associated with vascular disorders comprising an amount of a compound according to claim [12

Q2
Cont'd

Q3

106

ranging from 0.1 μ g to 200mg] 9 effective in treating such condition and a pharmaceutically acceptable carrier.

93
Conceded
12~~14~~. (amended) A pharmaceutical composition for treating disorders arising from deficient serotonergic neurotransmission comprising an amount of a compound according to claim [12 ranging from 0.1 μ g to 200mg] 9 effective in treating such a disorder and a pharmaceutically acceptable carrier.

13~~15~~. (amended) A method for treating a condition selected from hypertension, depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain and chronic paroxysmal hemicrania and headache associated with vascular disorders comprising administering to a mammal requiring such treatment an amount of a compound according to claim [12 ranging from 0.1 μ g to 200mg] 9 effective in treating such condition.

14~~16~~. (amended) A method for treating disorders arising from deficient serotonergic neurotransmission comprising administering to a mammal requiring such treatment an amount of a compound according to claim [12 ranging from 0.1 μ g to 200mg] 9 effective in treating such a disorder.

Please add the following new claims.

94
15~~35~~ ~~24~~. A pharmaceutical composition for treating a condition selected from hypertension, depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain, and chronic paroxysmal hemicrania and headache associated with vascular disorders comprising an amount of a compound according to claim 10 effective in treating such condition and a pharmaceutically acceptable carrier.

16~~36~~ ~~35~~. A pharmaceutical composition for treating disorders arising from deficient serotonergic neurotransmission comprising an amount of a compound according to claim 10 effective in treating such a disorder and a pharmaceutically acceptable carrier.

17~~37~~ ~~36~~. A method for treating a condition selected from hypertension, depression, anxiety, eating disorders,